These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 16307646)

  • 21. Germline splicing mutations of CDKN2A predispose to melanoma.
    Loo JC; Liu L; Hao A; Gao L; Agatep R; Shennan M; Summers A; Goldstein AM; Tucker MA; Deters C; Fusaro R; Blazer K; Weitzel J; Lassam N; Lynch H; Hogg D
    Oncogene; 2003 Sep; 22(41):6387-94. PubMed ID: 14508519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The p.G23S CDKN2A founder mutation in high-risk melanoma families from Central Italy.
    Gensini F; Sestini R; Piazzini M; Vignoli M; Chiarugi A; Brandani P; Ghiorzo P; Salvini C; Borgognoni L; Palli D; Bianchi-Scarrà G; Carli P; Genuardi M
    Melanoma Res; 2007 Dec; 17(6):387-92. PubMed ID: 17992122
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia.
    Ruiz A; Puig S; Malvehy J; Lázaro C; Lynch M; Gimenez-Arnau AM; Puig L; Sánchez-Conejo J; Estivill X; Castel T
    J Med Genet; 1999 Jun; 36(6):490-3. PubMed ID: 10874641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Familial melanoma, pancreatic cancer and germline CDKN2A mutations.
    Goldstein AM
    Hum Mutat; 2004 Jun; 23(6):630. PubMed ID: 15146471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of mutations in the p16/CDKN2A gene in sporadic and familial melanoma in the Polish population.
    Lamperska K; Karezewska A; Kwiatkowska E; Mackiewicz A
    Acta Biochim Pol; 2002; 49(2):369-76. PubMed ID: 12362978
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A common founder for the V126D CDKN2A mutation in seven North American melanoma-prone families.
    Goldstein AM; Liu L; Shennan MG; Hogg D; Tucker MA; Struewing JP
    Br J Cancer; 2001 Aug; 85(4):527-30. PubMed ID: 11506491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and genetic analysis of 18 pancreatic carcinoma/melanoma-prone families.
    Bartsch DK; Langer P; Habbe N; Matthäi E; Chaloupka B; Sina M; Hahn SA; Slater EP
    Clin Genet; 2010 Apr; 77(4):333-41. PubMed ID: 20041885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study.
    Casula M; Colombino M; Satta MP; Cossu A; Ascierto PA; Bianchi-Scarrà G; Castiglia D; Budroni M; Rozzo C; Manca A; Lissia A; Carboni A; Petretto E; Satriano SM; Botti G; Mantelli M; Ghiorzo P; Stratton MR; Tanda F; Palmieri G;
    J Clin Oncol; 2004 Jan; 22(2):286-92. PubMed ID: 14722037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutation screening of the CDKN2A promoter in melanoma families.
    Harland M; Holland EA; Ghiorzo P; Mantelli M; Bianchi-Scarrà G; Goldstein AM; Tucker MA; Ponder BA; Mann GJ; Bishop DT; Newton Bishop J
    Genes Chromosomes Cancer; 2000 May; 28(1):45-57. PubMed ID: 10738302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alport syndrome. Molecular genetic aspects.
    Hertz JM
    Dan Med Bull; 2009 Aug; 56(3):105-52. PubMed ID: 19728970
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CDKN2A (P16(INK4a)) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas.
    Holland EA; Schmid H; Kefford RF; Mann GJ
    Genes Chromosomes Cancer; 1999 Aug; 25(4):339-48. PubMed ID: 10398427
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of the neoplastic phenotype in the familial atypical multiple-mole melanoma-pancreatic carcinoma syndrome.
    Rulyak SJ; Brentnall TA; Lynch HT; Austin MA
    Cancer; 2003 Aug; 98(4):798-804. PubMed ID: 12910525
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families.
    Yakobson E; Eisenberg S; Isacson R; Halle D; Levy-Lahad E; Catane R; Safro M; Sobolev V; Huot T; Peters G; Ruiz A; Malvehy J; Puig S; Chompret A; Avril MF; Shafir R; Peretz H; Bressac-de Paillerets B
    Eur J Hum Genet; 2003 Apr; 11(4):288-96. PubMed ID: 12700603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple melanomas after treatment for Hodgkin lymphoma in a non-Dutch p16-Leiden mutation carrier with 2 MC1R high-risk variants.
    Figl A; Thirumaran RK; Ugurel S; Gast A; Hemminki K; Kumar R; Schadendorf D
    Arch Dermatol; 2007 Apr; 143(4):495-9. PubMed ID: 17438182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families.
    Peric B; Cerkovnik P; Novakovic S; Zgajnar J; Besic N; Hocevar M
    BMC Med Genet; 2008 Sep; 9():86. PubMed ID: 18803811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heterogeneity of risk for melanoma and pancreatic and digestive malignancies: a melanoma case-control study.
    Rutter JL; Bromley CM; Goldstein AM; Elder DE; Holly EA; Guerry D; Hartge P; Struewing JP; Hogg D; Halpern A; Sagebiel RW; Tucker MA
    Cancer; 2004 Dec; 101(12):2809-16. PubMed ID: 15529312
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy.
    Casula M; Colombino M; Satta MP; Cossu A; Lissia A; Budroni M; Simeone E; Calemma R; Loddo C; Caracò C; Mozzillo N; Daponte A; Comella G; Canzanella S; Guida M; Castello G; Ascierto PA; Palmieri G;
    Eur J Cancer; 2007 Jan; 43(1):137-43. PubMed ID: 17055252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The prevalence of CDKN2A germ-line mutations and relative risk for cutaneous malignant melanoma: an international population-based study.
    Berwick M; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Busam K; From L; Mujumdar U; Wilcox H; Begg CB;
    Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1520-5. PubMed ID: 16896043
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene-covariate interaction between dysplastic nevi and the CDKN2A gene in American melanoma-prone families.
    Goldstein AM; Martinez M; Tucker MA; Demenais F
    Cancer Epidemiol Biomarkers Prev; 2000 Sep; 9(9):889-94. PubMed ID: 11008905
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surveillance of second-degree relatives from melanoma families with a CDKN2A germline mutation.
    van der Rhee JI; Boonk SE; Putter H; Cannegieter SC; Flinterman LE; Hes FJ; de Snoo FA; Mooi WJ; Gruis NA; Vasen HF; Kukutsch NA; Bergman W
    Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1771-7. PubMed ID: 23897584
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.